Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Getein BiotechSHSE:603387 -0.32%75 5-Year Yield-on-Cost % is 2.46 as of Sep. 06, 2026, which is 37% above its 10-year median of 1.79. GuruFocus rates SHSE:603387 with a GF Score™ of 75/100 and a GF Value™ of ¥8.00 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 314 Medical Devices & Instruments companies, Getein Biotech ranks better than 50% on this metric.
Getein Biotech's yield on cost for the quarter that ended in Jun. 2026 was 2.46.
The historical rank and industry rank for Getein Biotech's 5-Year Yield-on-Cost % or its related term are showing as below:
SHSE:603387'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.51 Med: 1.79 Max: 4.9
Current: 2.46
During the past 13 years, Getein Biotech's highest Yield on Cost was 4.90. The lowest was 0.51. And the median was 1.79.
SHSE:603387's 5-Year Yield-on-Cost % is ranked better than 50% of 314
companies
in the Medical Devices & Instruments industry
Industry Median: 2.46
vs SHSE:603387: 2.46
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Getein Biotech 5-Year Yield-on-Cost % Related Terms
SHSE:603387 vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Getein Biotech's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Getein Biotech 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Getein Biotech's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Getein Biotech's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Getein Biotech is calculated as
Getein Biotech (SHSE:603387) has a 5-Year Yield-on-Cost % of 2.46 as of Sep. 06, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Getein Biotech and its competitors. This is 37% above median its historical median of 1.79. Over the past decade, Getein Biotech's 5-Year Yield-on-Cost % has ranged from 0.51 to 4.90. According to the industry distribution chart, Getein Biotech ranks #157 out of 314 companies in the Medical Devices & Instruments industry, placing it in the top 50%.
Is Getein Biotech's 5-Year Yield-on-Cost % too high?
Getein Biotech's current 5-Year Yield-on-Cost % of 2.46 is 37% above median its 10-year median of 1.79. Over the past 10 years, this metric has ranged from a low of 0.51 to a high of 4.90. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.46. Getein Biotech's value of 2.46 is 0% at this industry median. Based on the distribution chart, Getein Biotech ranks #157 out of 314 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Getein Biotech has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getein Biotech's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Getein Biotech ranks #157 out of 314 companies for 5-Year Yield-on-Cost %. This puts Getein Biotech in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.46. Getein Biotech's value of 2.46 is 0% at this benchmark. Historically, Getein Biotech's own 5-Year Yield-on-Cost % has ranged from 0.51 to 4.90 over the past decade. While the company's 10-year median is 1.79 vs. the industry median of 2.46, Getein Biotech has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.46, based on 314 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Getein Biotech's current 5-Year Yield-on-Cost % of 2.46 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Getein Biotech and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Getein Biotech's current 5-Year Yield-on-Cost % is 2.46, which is 37% above median its own 10-year median of 1.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Getein Biotech (SHSE:603387) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥8.00, compared to a current price of ¥9.27 — trading 15.9% above its estimated fair value. The current 5-Year Yield-on-Cost % is 2.46, which is 37% above median its 10-year median of 1.79 and 0% at the Medical Devices & Instruments industry median of 2.46. Getein Biotech's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Getein Biotech (SHSE:603387), the current 5-Year Yield-on-Cost % is 2.46 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Getein Biotech (SHSE:603387) Overvalued in 2026?
Based on GuruFocus' analysis, Getein Biotech stock appears to be overvalued.
The current stock price of ¥9.27 is trading 15.9% above its estimated GF Value™ of ¥8.00.
GuruFocus considers Getein Biotech to be Modestly Overvalued.
Key valuation signals for SHSE:603387:
5-Year Yield-on-Cost %: 2.46 (37% above median its 10-year median of 1.79)
GF Value™: ¥8.00 vs. price of ¥9.27 (15.9% above fair value)
Industry Position: 0% at the Medical Devices & Instruments median (#157 of 314)
No single metric tells the full story. See the SHSE:603387 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Getein Biotech Inc is an in-vitro diagnostic company. It is specializing in analytical medical devices and point-of-care testing kits. Its product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver and specialty assays.
75GF Score
Get the complete analysis for SHSE:603387
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603387 has been successfully added to your 
